...
首页> 外文期刊>Journal of lower genital tract disease. >Follow-up Testing After Colposcopy: Five-Year Risk of CIN 2+ After a Colposcopic Diagnosis of CIN 1 or Less
【24h】

Follow-up Testing After Colposcopy: Five-Year Risk of CIN 2+ After a Colposcopic Diagnosis of CIN 1 or Less

机译:阴道镜检查后的随访测试:阴道镜诊断CIN 1或以下后五年CIN 2+的风险

获取原文
获取原文并翻译 | 示例

摘要

Objective. Most women referred for colposcopy are not diagnosed with cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) but, nonetheless, are typically asked to return much sooner than their next routine screening interval in 3 to 5 years. An important question is how many subsequent negative Pap results, or negative Pap and human pap-illomavirus (HPV) cotest results, are needed before returning to an extended retesting interval.Methods. We estimated 5-year risks of CIN 2+ for 3 follow-up management strategies after colposcopy (Pap-alone, HPV-alone, and cotesting) for 20,319 women aged 25 years and older screened from 2003 to 2010 at Kaiser Permanente Northern California who were referred for colposcopy but for whom CIN 2+ was not initially diagnosed (i.e., "women with CIN 1egative colposcopy").Results. Screening results immediately antecedent to CIN 1egative colposcopy influenced subsequent 5-year CIN 2+ risk: women with an antecedent HPV-positive/ atypical squamous cells of undetermined significance (ASCIIS) or low-grade squamous intraepithelial lesion (LSIL) Pap had a lower risk (10%) than those with antecedent atypical squamous cells cannot rule out HSIL (ASC-H; 16%, p < .0001) or high-grade squamous intraepithelial lesion or worse (HSIL+; 24%, p < .0001). For women with an antecedent HPV-positive/ASC-US or LSIL, a single negative cotest approximately 1 year after colposcopy predicted lower subsequent 5-year risk of CIN 2+ (1.1%) than 2 sequential negative HPV tests (1.8%, p = .3) or 2 sequential negative Pap results (4.0%, p < .0001). For those with an antecedent ASC-H or HSIL+ Pap, 1 negative cotest 1 year after colposcopy predicted lower subsequent 5-year risk of CIN 2+ (2.2%) than 1 negative HPV test (4.4%, p = .4) or 1 negative Pap (7.0%, p = .06); insufficient data existed to calculate the risk after sequential negative cotests for women with high-grade antecedent cytology.Conclusions. Women with a CIN 1egative colposcopy followed by negative postcolposcopy tests did not achieve sufficiently low CIN 2+ risk to return to 5-year routine screening. For women with antecedent HPV-positive/ASC-US or LSIL, a single negative postcolposcopy cotest reduced their risk to a level consistent with a 3-year return. For women with antecedent ASC-H or HSIL+, no single negative test result sufficed to reduce their risk to a level consistent with a 3-year return.
机译:目的。大多数接受阴道镜检查的妇女并未被诊断出患有2级或更严重的宫颈上皮内瘤变(CIN 2+),但通常要求她们比下一次常规筛查间隔3至5年要早得多。一个重要的问题是,在返回延长的重新测试间隔之前,需要多少次后续的Pap阴性结果或Pap与人乳头瘤病毒(HPV)共同测试结果。我们估计了2003年至2010年在北加州凯撒永久医学中心接受筛查的20,319名年龄在25岁以上的女性的阴道镜检查(单独使用Pap,仅HPV和联合测试)后3种随访管理策略中CIN 2+的5年风险。接受阴道镜检查,但最初并未诊断为CIN 2+(即“ CIN 1 /阴性阴道镜检查的妇女”)。 CIN 1 /阴性阴道镜检查之前的筛查结果立即影响了随后的5年CIN 2+风险:HPV阳性/不典型意义(ASCIIS)或低度鳞状上皮内病变(LSIL)Pap的女性前房性HPV阳性较不典型非典型鳞状细胞癌的风险低(10%),不能排除HSIL(ASC-H; 16%,p <.0001)或高度鳞状上皮内病变或更严重(HSIL +; 24%,p <.0001) 。对于HPV阳性/ ASC-US或LSIL较早的女性,阴道镜检查后约1年的一次阴性联合测试预测,其随后5年CIN 2+的风险(1.1%)低于连续2次阴性HPV测试(1.8%, = 0.3)或2个连续的阴性Pap结果(4.0%,p <.0001)。对于那些先前ASC-H或HSIL + Pap的患者,阴道镜检查1年后1次阴性共测预示其随后5年CIN 2+风险(2.2%)低于1次HPV阴性(4.4%,p = .4)或1负子宫颈癌(7.0%,p = .06);尚无足够的数据来计算先行细胞学检查阴性的女性在进行顺序阴性试验后的风险。 CIN 1 /阴性阴道镜检查后阴道镜检查阴性的女性未达到足够低的CIN 2+风险,无法返回5年常规筛查。对于HPV阳性/ ASC-US或LSIL较早的女性,一次阴道镜检查后阴性共测验可将其风险降低至与3年回报率一致的水平。对于ASC-H或HSIL +前期的女性,没有任何一项阴性测试结果足以将其风险降低至与3年回报率一致的水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号